1 Hofman MS, "[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer(LuPSMA trial) : a single-centre, single-arm, phase 2 study" 19 : 825-833, 2018
2 Niemeijer AN, "Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer" 9 : 4664-, 2018
3 Heck MM, "Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer" 75 : 920-926, 2019
4 Zhang J, "The influence of microenvironment on tumor immunotherapy" 286 : 4160-4175, 2019
5 Lanitis E, "Targeting the tumor vasculature to enhance T cell activity" 33 : 55-63, 2015
6 Xia A, "T cell dysfunction in cancer immunity and immunotherapy" 10 : 1719-, 2019
7 Teichgräber V, "Specific inhibition of fibroblast activation protein(FAP)-alpha prevents tumor progression in vitro" 60 : 264-272, 2015
8 Herrera FG, "Radiotherapy combination opportunities leveraging immunity for the next oncology practice" 67 : 65-85, 2017
9 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists" 51 : 987-994, 2010
10 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma : opinions of nuclear medicine physicians and radiation oncologists" 52 : 830-838, 2011
1 Hofman MS, "[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer(LuPSMA trial) : a single-centre, single-arm, phase 2 study" 19 : 825-833, 2018
2 Niemeijer AN, "Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer" 9 : 4664-, 2018
3 Heck MM, "Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer" 75 : 920-926, 2019
4 Zhang J, "The influence of microenvironment on tumor immunotherapy" 286 : 4160-4175, 2019
5 Lanitis E, "Targeting the tumor vasculature to enhance T cell activity" 33 : 55-63, 2015
6 Xia A, "T cell dysfunction in cancer immunity and immunotherapy" 10 : 1719-, 2019
7 Teichgräber V, "Specific inhibition of fibroblast activation protein(FAP)-alpha prevents tumor progression in vitro" 60 : 264-272, 2015
8 Herrera FG, "Radiotherapy combination opportunities leveraging immunity for the next oncology practice" 67 : 65-85, 2017
9 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists" 51 : 987-994, 2010
10 Schaefer NG, "Radioimmunotherapy in non-Hodgkin lymphoma : opinions of nuclear medicine physicians and radiation oncologists" 52 : 830-838, 2011
11 Conway RE, "Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction" 26 : 5310-5324, 2006
12 Strosberg J, "Phase 3 trial of(177)Lu-dotatate for midgut neuroendocrine tumors" 376 : 125-135, 2017
13 DeriMA, "PETimaging with 89Zr : fromradiochemistry to the clinic" 40 : 3-14, 2013
14 Blykers A, "PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18Fradiolabeled camelid single-domain antibody fragments" 56 : 1265-1271, 2015
15 Zhang C, "Noninvasive imaging of CD206-positiveM2macrophages as an early biomarker for post-chemotherapy tumor relapse and lymph node metastasis" 7 : 4276-4288, 2017
16 Emmett L, "Lutetium177PSMA radionuclide therapy for men with prostate cancer : a review of the current literature and discussion of practical aspects of therapy" 64 : 52-60, 2017
17 Klug F, "Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective Tcell immunotherapy" 24 : 589-602, 2013
18 Calais J, "FAP : the next billion dollar nuclear theranostics target" 61 : 163-165, 2020
19 Jiao D, "Expression of prostate-specificmembrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma" 10 : e00041-, 2019
20 Tavare R, "An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy" 76 : 73-82, 2016
21 Bensch F, "89Zr-atezolizumab imaging as a noninvasive approach to assess clinical response to PD-L1 blockade in cancer" 24 : 1852-1858, 2018
22 Kratochwil C, "225Ac-PSMA-617 for PSMA-targeted-radiation therapy of metastatic castration-resistant prostate cancer" 57 : 1941-1944, 2016
23 Giesel FL, "(68)Ga-FAPI PET/CT : biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers" 60 : 386-392, 2019